JP2022536287A5 - - Google Patents
Info
- Publication number
- JP2022536287A5 JP2022536287A5 JP2021571931A JP2021571931A JP2022536287A5 JP 2022536287 A5 JP2022536287 A5 JP 2022536287A5 JP 2021571931 A JP2021571931 A JP 2021571931A JP 2021571931 A JP2021571931 A JP 2021571931A JP 2022536287 A5 JP2022536287 A5 JP 2022536287A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- dose
- demand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131860A JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861725P | 2019-06-14 | 2019-06-14 | |
| US62/861,725 | 2019-06-14 | ||
| GBGB1910116.1A GB201910116D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of hereditary angioedema |
| GB1910116.1 | 2019-07-15 | ||
| PCT/GB2020/051439 WO2020249977A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of hereditary angioedema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131860A Division JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536287A JP2022536287A (ja) | 2022-08-15 |
| JP2022536287A5 true JP2022536287A5 (https=) | 2023-01-23 |
| JP7356518B2 JP7356518B2 (ja) | 2023-10-04 |
Family
ID=67700145
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571931A Active JP7356518B2 (ja) | 2019-06-14 | 2020-06-15 | 遺伝性血管性浮腫の治療 |
| JP2023131860A Active JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A Pending JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131860A Active JP7688078B2 (ja) | 2019-06-14 | 2023-08-14 | 遺伝性血管性浮腫の治療 |
| JP2025084646A Pending JP2025124716A (ja) | 2019-06-14 | 2025-05-21 | 遺伝性血管性浮腫の治療 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20220218680A1 (https=) |
| EP (2) | EP4282474A3 (https=) |
| JP (3) | JP7356518B2 (https=) |
| KR (1) | KR102748728B1 (https=) |
| CN (1) | CN114126612A (https=) |
| AR (1) | AR119158A1 (https=) |
| AU (1) | AU2020293614B2 (https=) |
| BR (1) | BR112021024664A2 (https=) |
| CA (1) | CA3142218A1 (https=) |
| CL (2) | CL2021003244A1 (https=) |
| DK (1) | DK3982960T3 (https=) |
| EA (1) | EA202193019A1 (https=) |
| ES (1) | ES2956471T3 (https=) |
| FI (1) | FI3982960T3 (https=) |
| GB (1) | GB201910116D0 (https=) |
| HR (1) | HRP20230696T1 (https=) |
| HU (1) | HUE063163T2 (https=) |
| IL (1) | IL288615A (https=) |
| LT (1) | LT3982960T (https=) |
| MA (1) | MA56187B1 (https=) |
| MD (1) | MD3982960T2 (https=) |
| MX (1) | MX2021014557A (https=) |
| MY (1) | MY205687A (https=) |
| PH (1) | PH12021552966A1 (https=) |
| PL (1) | PL3982960T3 (https=) |
| PT (1) | PT3982960T (https=) |
| RS (1) | RS64412B1 (https=) |
| SG (1) | SG11202113304YA (https=) |
| SI (1) | SI3982960T1 (https=) |
| SM (1) | SMT202300261T1 (https=) |
| TW (1) | TW202112370A (https=) |
| UA (1) | UA129869C2 (https=) |
| WO (1) | WO2020249977A1 (https=) |
| ZA (1) | ZA202110685B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4232031A1 (en) * | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| EP4480545A3 (en) | 2022-04-27 | 2025-02-26 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2026003532A1 (en) | 2024-06-28 | 2026-01-02 | Kalvista Pharmaceuticals Limited | Sebetralstat for the treatment of anxiety associated with hereditary angioedema |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
-
2019
- 2019-07-15 GB GBGB1910116.1A patent/GB201910116D0/en not_active Ceased
-
2020
- 2020-06-15 CN CN202080043365.6A patent/CN114126612A/zh active Pending
- 2020-06-15 RS RS20230620A patent/RS64412B1/sr unknown
- 2020-06-15 AU AU2020293614A patent/AU2020293614B2/en active Active
- 2020-06-15 HR HRP20230696TT patent/HRP20230696T1/hr unknown
- 2020-06-15 EP EP23181261.1A patent/EP4282474A3/en active Pending
- 2020-06-15 PL PL20734283.3T patent/PL3982960T3/pl unknown
- 2020-06-15 SG SG11202113304YA patent/SG11202113304YA/en unknown
- 2020-06-15 CA CA3142218A patent/CA3142218A1/en active Pending
- 2020-06-15 BR BR112021024664A patent/BR112021024664A2/pt not_active Application Discontinuation
- 2020-06-15 UA UAA202106869A patent/UA129869C2/uk unknown
- 2020-06-15 LT LTEPPCT/GB2020/051439T patent/LT3982960T/lt unknown
- 2020-06-15 MY MYPI2021007320A patent/MY205687A/en unknown
- 2020-06-15 WO PCT/GB2020/051439 patent/WO2020249977A1/en not_active Ceased
- 2020-06-15 FI FIEP20734283.3T patent/FI3982960T3/fi active
- 2020-06-15 KR KR1020217043374A patent/KR102748728B1/ko active Active
- 2020-06-15 ES ES20734283T patent/ES2956471T3/es active Active
- 2020-06-15 SI SI202030247T patent/SI3982960T1/sl unknown
- 2020-06-15 EA EA202193019A patent/EA202193019A1/ru unknown
- 2020-06-15 DK DK20734283.3T patent/DK3982960T3/da active
- 2020-06-15 HU HUE20734283A patent/HUE063163T2/hu unknown
- 2020-06-15 MD MDE20220440T patent/MD3982960T2/ro unknown
- 2020-06-15 PH PH1/2021/552966A patent/PH12021552966A1/en unknown
- 2020-06-15 US US17/617,439 patent/US20220218680A1/en active Pending
- 2020-06-15 TW TW109120108A patent/TW202112370A/zh unknown
- 2020-06-15 EP EP20734283.3A patent/EP3982960B1/en active Active
- 2020-06-15 PT PT207342833T patent/PT3982960T/pt unknown
- 2020-06-15 JP JP2021571931A patent/JP7356518B2/ja active Active
- 2020-06-15 MA MA56187A patent/MA56187B1/fr unknown
- 2020-06-15 MX MX2021014557A patent/MX2021014557A/es unknown
- 2020-06-15 SM SM20230261T patent/SMT202300261T1/it unknown
- 2020-06-16 AR ARP200101681A patent/AR119158A1/es unknown
-
2021
- 2021-12-02 IL IL288615A patent/IL288615A/en unknown
- 2021-12-06 CL CL2021003244A patent/CL2021003244A1/es unknown
- 2021-12-20 ZA ZA2021/10685A patent/ZA202110685B/en unknown
-
2023
- 2023-03-06 CL CL2023000639A patent/CL2023000639A1/es unknown
- 2023-08-14 JP JP2023131860A patent/JP7688078B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084646A patent/JP2025124716A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536287A5 (https=) | ||
| FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
| JP2022537913A5 (https=) | ||
| TW200838545A (en) | Therapeutic agent for painful disease | |
| US11318144B2 (en) | Compositions and methods for treating Alzheimer's disease and Parkinson's disease | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| TW202545526A (zh) | 低劑量三重組合調配物 | |
| CA3107624C (en) | Composition for eradicating helicobacter pylori | |
| JPH0920659A (ja) | 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬 | |
| CN115776885A (zh) | 用于治疗阿尔茨海默病和帕金森病的组合物和方法 | |
| JP2022529208A5 (https=) | ||
| JP2016507500A5 (https=) | ||
| WO2005034936A1 (en) | Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct | |
| WO2023280238A1 (zh) | 一种包含绿原酸的药物组合物在制备治疗早期阿尔茨海默病的药物中的用途 | |
| JP2023531930A5 (https=) | ||
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| CN1263465A (zh) | 利用选择性5－羟色胺再摄取抑制剂治疗和预防心脏病 | |
| WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| CN101014333A (zh) | 包含洛索洛芬的口服组合物 | |
| EA029932B1 (ru) | Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции | |
| CN114080221B (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| CN112569357B (zh) | 双重内皮素受体拮抗剂与利尿剂的组合物 | |
| JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
| JP2026500731A (ja) | 医薬組合せおよび医薬組成物、ならびにその使用方法 | |
| TW201206433A (en) | Association of xanthine oxidase inhibitors and calcium antagonists and use thereof |